News | April 14, 2025
Novartis to invest $23 billion on expansion of manufacturing and R&D facilities in US
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla
This registration authorizes Nureca Technologies to continue manufacturing and exporting asuite of medical devices to the United States
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
The company has entered into above Memo to settle, compromise and finally and forever resolve all disputes
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance
Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI
Sharma brings a wealth of expertise in optimizing manufacturing processes for fermentation-based APIs and sterile injectables
Strengthening capabilities in Peptide Therapeutics and CDMO services
Subscribe To Our Newsletter & Stay Updated
